Disclosures: Francisco Caballero-Camino: Nothing to Disclose, Irune Lasa: Nothing to Disclose, Ainhoa Lapitz: Nothing to Disclose, Xia Wu: CymaBay Therapeutics: Employee, Pedro Rodrigues: Nothing to Disclose, Noelia Pastor-Toyos: Nothing to Disclose, Laura Izquierdo-Sanchez: Nothing to Disclose, Jiangao Song: Nothing to Disclose, Edward Cable: CymaBay Therapetics: Employee, Jeffrey Johnson: CymaBay Therapeutics: Consultant, Yun-Jung Choi: Nothing to Disclose, Charles McWherter: Nothing to Disclose, Jesus Banales: Nothing to Disclose 2077 REGULATION OF HEPATIC MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3/ATP-BINDING CASSETTE SUBFAMILY C MEMBER 3 (MRP3/ABCC3) BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR): A NOVEL MECHANISM TO REDUCE BILE ACID INJURY DURING CHOLESTASIS Colleen Hayes 1 Gina Gallucci 1 James Boyer 2 David Assis 2 Nisanne Ghonem 1 , 1 University of Rhode Island, 2 Yale School of Medicine, Liver Center Background: Cholestatic liver diseases are characterized by the accumulation of toxic bile acids
The presenter highlights the strong start of Foundayo's U.S
They can help you find solutions, whether that's getting a new prescription, finding patient assistance programs, or exploring alternative medications
If your insurance doesnt cover your GLP-1 medication, dont worry - there are several ways to manage the cost
Diabetes 13, 3 (2023)
